DBT launches national initiative to identify biomarkers for preterm births

The first-phase of the Grand Challenge Program to identify the causes behind a preterm birth, has a total financial outlay of Rs 48.85 crore for a period of 5 years


Finding the root cause of Preterm births: It is for the first time in India that a national program is being launched to collect the data

After a series of national and international consultations, the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India has launched a major national program to identify the correlates, causes, and predictive biomarkers of preterm birth under its Grand Challenge Program. The first-phase of the initiative has been allocated Rs 48.85 crore for 5 years.

A birth that takes place before the mother has been pregnant for at least 37 weeks construes a preterm birth. In India, among the total 27 million babies born annually, 3.6 million babies are born preterm, and over 300,000 of these preterm babies die each year because of associated complications. India, with its highest number of PTBs and the highest number of preterm deaths worldwide, contributes 25 percent of the overall global preterm related deaths. The effects of PTB extend beyond early infancy with substantial long-term consequences in late childhood and adult life.

The objective of DBT's program is to collect scientific information on pregnancy that may lead to a preterm birth, a pregnancy has to be identified early, followed up through the duration of the pregnancy during which clinical and life-style information must be collected. Biological changes taking place during this period must also be assayed by collecting blood and other biological materials from the pregnant woman. Further, because differences in biological responses and life-style factors are enormous among pregnant women, information needs to be collected on a large cohort.

The overall long term goals are to stratify women early in pregnancy or before conception into various levels of risk of PTB, identify simple and better prediction tools that will recognize the optimal time of prediction and clinical intervention, develop additional strategies to identify presence of unusual or novel microbes that could serve as biomarkers; identify focused remedies targeting one or more mechanistic pathways (e.g. infection, inflammation, hormonal), and apply currently available interventions (tocolytic agents) based on better understanding of biological mechanisms.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email